Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 60 mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - azelastine hydrochloride (unii: 0l591qr10i) (azelastine - unii:zqi909440x) - azelastine hydrochloride 137 ug in 0.137 ml - azelastine hydrochloride nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older. none. pregnancy category c there are no adequate and well-controlled clinical studies in pregnant women. azelastine hydrochloride has been shown to cause developmental toxicity in mice, rats, and rabbits. azelastine hydrochloride nasal spray should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. teratogenic effects in mice, azelastine hydrochloride caused embryo-fetal death, malformations (cleft palate; short or absent tail; fused, absent or branched ribs), delayed ossification, and decreased fetal weight at approximately 170 times the maximum recommended human daily intranasal dose (mrhdid) in adults (on a mg/m2 basis at a maternal oral dose of 68.6 mg/kg/day, which also caused mater

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - amantadine hydrochloride (unii: m6q1eo9td0) (amantadine - unii:bf4c9z1j53) - amantadine hydrochloride 100 mg - amantadine hydrochloride capsules, usp are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza a virus. amantadine hydrochloride capsules, usp are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. amantadine hydrochloride capsules, usp are indicated for chemoprophylaxis against signs and symptoms of influenza a virus infection. because amantadine does not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. following vaccination during an influenza a outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. amantadine hydrochloride capsules, usp are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza a vi

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

upsher-smith laboratories, llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 600 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal s

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 1500 mg - because of reports of intestinal and gastric ulceration and bleeding with extended-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 600 mg

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

upsher-smith laboratories, inc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide 100 mg in 1 g

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - potassium bicarbonate (unii: hm5z15lebn) (potassium cation - unii:295o53k152) - - for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop (e.g., digitalized patients or patients with significant cardiac arrhythmias). the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwarra

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - potassium bicarbonate (unii: hm5z15lebn) (potassium cation - unii:295o53k152) - potassium cation 978 mg - - for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop (e.g., digitalized patients or patients with significant cardiac arrhythmias). the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwarra

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), calcium (unii: sy7q814vup) (calcium - unii:sy7q814vup), phosphorus (unii: 27ylu75u4w) (phosphorus - unii:27ylu75u4w) - cholecalciferol 2000 [iu]